MAP2K1 and cystic fibrosis: Our previous studies using non-CF human macrophages and wild-type mice demonstrated that MEK1/2 inhibitors modulated macrophage polarization in vitro and in vivo, and mitigated illness in wild-type mice when therapeutically delivered after initiation of experimental LPS-induced acute lung injury or P. aeruginosa pneumonia (Long et al., 2017a; Long et al., 2017b).